Government and Regulations

Anthrax Antitoxin Drugs Added to the Stockpile

According to HHS, the anthrax antitoxin drugs Anthim and raxibacumab are being added to the Strategic National Stockpile.


Two types of anthrax antitoxin drugs to treat inhalational anthrax are being added to the Strategic National Stockpile, according to HHS.

Anthim is a monoclonal antibody that binds to a key bacterial protein and reduces anthrax’s toxic effects. Through a $44.9 million agreement with the manufacturer, Anthim becomes the fourteenth product added to the stockpile since 2004.

The second drug, raxibacumab, is replacing expiring doses. Raxibacumab, also a monoclonal antibody, was the first anthrax antitoxin approved by the FDA. The Biomedical Advanced Research and Development Authority of the HHS Office of the Assistant Secretary for Preparedness and Response is providing $9.7 million to ensure a supply of raxibacumab through 2019.

Recommended Reading

New Developments in Adult Vaccination: Challenges and Opportunities to Protect Vulnerable Veterans From Pneumococcal Disease
Federal Practitioner
Therapeutic Interchange From Rosuvastatin to Atorvastatin in a Veteran Population
Federal Practitioner
Treatment Failure With Atorvastatin After Change From Rosuvastatin to Atorvastatin
Federal Practitioner
Implications of Vancomycin Troughs Drawn Earlier Than Current Guidelines
Federal Practitioner
Shared Medical Appointments and Their Effects on Achieving Diabetes Mellitus Goals in a Veteran Population
Federal Practitioner

Related Articles

  • Government and Regulations

    New Guidance on Compounded Drugs

    As of May 1, 2015, a new screening process will take effect for compounded drugs, which make up only 0.5% of total TRICARE prescriptions but...

  • Government and Regulations

    A New Kind of Flu Drug

    Studies suggest an experimental influenza drug may provide clinical benefits even when administered later than 48 hours after symptom onset.